Earnings calls

Windlas Biotech concall ledger

Every earnings call for WINDLAS — management tone, guidance, KPIs and promise tracking, quarter by quarter.

WINDLAS · 4 transcripts · Healthcare · latest Q3 FY26

Q3 FY26Published 11 Feb 2026Call held 11 Feb 2026

WINDLAS Q3 FY26 Earnings Call Transcript & Analysis

Revenue₹233 cr+20% YoYEBITDA₹32 crEBITDA Margin13.6%PAT₹22 crPAT Margin9.6%

Revenue (Q3 FY26) ₹233 cr (+20% YoY); EBITDA (Q3 FY26, ex-ESOP) ₹32 cr; EBITDA Margin (Q3 FY26, ex-ESOP) 13.6%. Q3 FY26 revenue from operations grew 20% YoY to INR233 crores.

Read full transcript & analysis

Q2 FY26Published 07 Nov 2025Call held 07 Nov 2025

WINDLAS Q2 FY26 Earnings Call Transcript & Analysis

Revenue₹222 cr+19% YoYEBITDA₹29 crEBITDA Margin13.5%PAT₹18 crGross Margin—+1% YoY

Revenue ₹222 cr (+19% YoY); EBITDA ₹29 cr; EBITDA Margin (Q2 FY26 ex-ESOP) 13.5%. Revenue increased by 19% YoY in both Q2 FY26 and H1 FY26.

Read full transcript & analysis

Q1 FY26Published 13 Aug 2025Call held 13 Aug 2025

WINDLAS Q1 FY26 Earnings Call Transcript & Analysis

Revenue₹210 cr+20% YoYEBITDA₹27 cr+27% YoYEBITDA Margin12.6%+1% YoYPAT₹18 cr+31% YoYGross Margin38.3%+1% YoY

Revenue ₹210 cr (+20% YoY); EBITDA ₹27 cr (+27% YoY); EBITDA Margin 12.6% (+1% YoY). Revenue grew 20% Y-o-Y to INR 210 crores.

Read full transcript & analysis

Q4 FY25Published 23 May 2025Call held 23 May 2025

WINDLAS Q4 FY25 Earnings Call Transcript & Analysis

Revenue₹759 cr+20% YoYEBITDA₹94.1 cr+20% YoYPAT₹61 cr+5% YoYEPS₹29.19

Revenue (FY25) ₹759 cr (+20% YoY); EBITDA (FY25) ₹94 cr (+20% YoY); PAT (FY25) ₹61 cr (+5% YoY). FY25 Revenue of INR759 crores, up 20.4% YoY.

Read full transcript & analysis